NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Individual Patient Compassionate Use of Mirdametinib

AvailableN/A

Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Conditions: Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, Histiocytic Neoplasm, Other MAP-K Pathway Driven Diseases

Interventions: Mirdametinib (MEK Inhibitor)

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.

Eligibility overview

Sex: ALL

Age: 2 Years to —

Study type: EXPANDED_ACCESS

Eligibility criteria

Inclusion Criteria:

* Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted.
* Patient does not qualify to participate in an ongoing clinical trial.